BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36171333)

  • 21. Deletion of HNF1α in hepatocytes results in fatty liver-related hepatocellular carcinoma in mice.
    Ni Q; Ding K; Wang KQ; He J; Yin C; Shi J; Zhang X; Xie WF; Shi YQ
    FEBS Lett; 2017 Jul; 591(13):1947-1957. PubMed ID: 28547778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of Probiotics and
    Wang W; Xu AL; Li ZC; Li Y; Xu SF; Sang HC; Zhi F
    Diabetes Metab J; 2020 Apr; 44(2):336-348. PubMed ID: 31950772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apoptosis and non-alcoholic fatty liver diseases.
    Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
    World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells.
    Luo X; Liao R; Hanley KL; Zhu HH; Malo KN; Hernandez C; Wei X; Varki NM; Alderson N; Chu C; Li S; Fan J; Loomba R; Qiu SJ; Feng GS
    Cell Rep; 2016 Dec; 17(11):2979-2993. PubMed ID: 27974211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
    Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L
    Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225
    [No Abstract]   [Full Text] [Related]  

  • 28. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma.
    Corbit KC; Wilson CG; Lowe D; Tran JL; Vera NB; Clasquin M; Mattis AN; Weiss EJ
    JCI Insight; 2019 Aug; 5(17):. PubMed ID: 31393852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR/Cas9-based Pten knock-out and Sleeping Beauty Transposon-mediated Nras knock-in induces hepatocellular carcinoma and hepatic lipid accumulation in mice.
    Gao M; Liu D
    Cancer Biol Ther; 2017 Jul; 18(7):505-512. PubMed ID: 28513320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.
    Endo H; Niioka M; Kobayashi N; Tanaka M; Watanabe T
    PLoS One; 2013; 8(5):e63388. PubMed ID: 23696823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of hepatocyte mitochondrial function by blueberry juice and probiotics via SIRT1 regulation in non-alcoholic fatty liver disease.
    Ren T; Zhu L; Shen Y; Mou Q; Lin T; Feng H
    Food Funct; 2019 Mar; 10(3):1540-1551. PubMed ID: 30785444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
    Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
    Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells.
    Goonetilleke M; Kuk N; Correia J; Hodge A; Moore G; Gantier MP; Yeoh G; Sievert W; Lim R
    Stem Cell Res Ther; 2021 Jul; 12(1):429. PubMed ID: 34321089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
    Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
    Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of FGF21 promotes NASH-HCC transition
    Zheng Q; Martin RC; Shi X; Pandit H; Yu Y; Liu X; Guo W; Tan M; Bai O; Meng X; Li Y
    Theranostics; 2020; 10(22):9923-9936. PubMed ID: 32929325
    [No Abstract]   [Full Text] [Related]  

  • 38. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
    Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
    Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
    [No Abstract]   [Full Text] [Related]  

  • 39. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.